메뉴 건너뛰기




Volumn 23, Issue 6, 2005, Pages 374-384

Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

CARBOLINE DERIVATIVE; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; IMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SILDENAFIL; SULFONE; TADALAFIL; TRIAZINE DERIVATIVE; VARDENAFIL;

EID: 31144472373     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-005-0022-6     Document Type: Review
Times cited : (29)

References (75)
  • 1
    • 0036192355 scopus 로고    scopus 로고
    • Molecular mechanisms for the regulation of penile smooth muscle contractility
    • 10.1038/sj.ijir.3900790
    • Sáenz de Tejada I (2002) Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 14(Suppl. 1):S6-S10 10.1038/sj.ijir.3900790
    • (2002) Int J Impot Res , vol.14 , Issue.SUPPL. 1
    • Sáenz de Tejada, I.1
  • 3
    • 0025081992 scopus 로고
    • Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle
    • 10.1016/0006-291X(90)92168-Y
    • Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto GM, Rajfer J (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170:839-843 10.1016/0006-291X(90)92168-Y
    • (1990) Biochem Biophys Res Commun , vol.170 , pp. 839-843
    • Ignarro, L.J.1    Bush, P.A.2    Buga, G.M.3    Wood, K.S.4    Fukuto, G.M.5    Rajfer, J.6
  • 4
    • 0025733506 scopus 로고
    • A nitric-oxide like factor mediates nonadrenergic noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle
    • 1647413
    • Kim N, Azadzoi KM, Goldstein I, Sáenz de Tejada I (1991) A nitric-oxide like factor mediates nonadrenergic noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 88:112-118 1647413
    • (1991) J Clin Invest , vol.88 , pp. 112-118
    • Kim, N.1    Azadzoi, K.M.2    Goldstein, I.3    Sáenz de Tejada, I.4
  • 6
    • 0026093557 scopus 로고
    • Effects of nitric oxide synthase inhibitor Ng-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit
    • 1722938
    • Holmquist F, Stief CG, Jonas U, Andersson KE (1991) Effects of nitric oxide synthase inhibitor Ng-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol Scand 143:299-304 1722938
    • (1991) Acta Physiol Scand , vol.143 , pp. 299-304
    • Holmquist, F.1    Stief, C.G.2    Jonas, U.3    Andersson, K.E.4
  • 7
    • 0034086679 scopus 로고    scopus 로고
    • Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis
    • 10.1159/000020262
    • Kuthe A, Magert H, Ückert S, Forssman WG, Stief CG, Jonas U (2000) Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol 38:108-114 10.1159/000020262
    • (2000) Eur Urol , vol.38 , pp. 108-114
    • Kuthe, A.1    Magert, H.2    Ückert, S.3    Forssman, W.G.4    Stief, C.G.5    Jonas, U.6
  • 8
    • 0035257809 scopus 로고    scopus 로고
    • Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction
    • 11289565
    • Ückert S, Kuthe A, Stief CG, Jonas U (2001) Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 19:14-22 11289565
    • (2001) World J Urol , vol.19 , pp. 14-22
    • Ückert, S.1    Kuthe, A.2    Stief, C.G.3    Jonas, U.4
  • 9
    • 0034992660 scopus 로고    scopus 로고
    • Pharmacology of erectile function and dysfunction
    • 10.1016/S0094-0143(05)70134-8
    • Andersson KE (2001) Pharmacology of erectile function and dysfunction. Urol Clin North Am 28:233-247 10.1016/S0094-0143(05)70134-8
    • (2001) Urol Clin North Am , vol.28 , pp. 233-247
    • Andersson, K.E.1
  • 10
    • 0036194396 scopus 로고    scopus 로고
    • New directions for erectile dysfunction therapies
    • 10.1038/sj.ijir.3900797
    • Andersson KE, Hedlund P (2002) New directions for erectile dysfunction therapies. Int J Impot Res 14(Suppl. 1):S82-S92 10.1038/sj.ijir.3900797
    • (2002) Int J Impot Res , vol.14 , Issue.SUPPL. 1
    • Andersson, K.E.1    Hedlund, P.2
  • 11
    • 0034673250 scopus 로고    scopus 로고
    • Expression of three isoforms of cGMP binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum
    • 10.1006/bbrc.2000.2187
    • Lin CS, Lau A, Tu R, Lue TF (2000) Expression of three isoforms of cGMP binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 268:628-635 10.1006/bbrc.2000.2187
    • (2000) Biochem Biophys Res Commun , vol.268 , pp. 628-635
    • Lin, C.S.1    Lau, A.2    Tu, R.3    Lue, T.F.4
  • 13
    • 0037685679 scopus 로고    scopus 로고
    • Viagra labelling information
    • U.S. Food and Drug Administration submission Pfizer, New York
    • U.S. Food and Drug Administration submission (1997) Viagra labelling information. Pfizer, New York
    • (1997)
  • 14
    • 0034029120 scopus 로고    scopus 로고
    • In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions
    • 10725306
    • Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ (2000) In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28:392-397 10725306
    • (2000) Drug Metab Dispos , vol.28 , pp. 392-397
    • Warrington, J.S.1    Shader, R.I.2    von Moltke, L.L.3    Greenblatt, D.J.4
  • 15
    • 0033046143 scopus 로고    scopus 로고
    • Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies
    • 10.1016/S0090-4295(98)00643-8
    • Montorsi F, McDermott T, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH (1999) Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53:1011-1018 10.1016/S0090-4295(98)00643-8
    • (1999) Urology , vol.53 , pp. 1011-1018
    • Montorsi, F.1    McDermott, T.2    Morgan, R.3    Olsson, A.4    Schultz, A.5    Kirkeby, H.J.6    Osterloh, I.H.7
  • 16
    • 0033661495 scopus 로고    scopus 로고
    • Sildenafil: Clinical toxicology profile
    • 10.1081/CLT-100102015
    • Krenzelok EP (2000) Sildenafil: Clinical toxicology profile. J Toxicol Clin Toxicol 38:645-651 10.1081/CLT-100102015
    • (2000) J Toxicol Clin Toxicol , vol.38 , pp. 645-651
    • Krenzelok, E.P.1
  • 17
    • 0036124906 scopus 로고    scopus 로고
    • A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction
    • 10.1046/j.0306-5251.2001.00032.x
    • Milligan PA, Marshall SF, Karlsson MO (2002) A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 53:S45-S52 10.1046/ j.0306-5251.2001.00032.x
    • (2002) Br J Clin Pharmacol , vol.53
    • Milligan, P.A.1    Marshall, S.F.2    Karlsson, M.O.3
  • 19
    • 0001825459 scopus 로고    scopus 로고
    • Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families
    • Gbekor E, Bethell S, Fawcett L, Mount N, Phillips S (2002) Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 1(Suppl. 1):63
    • (2002) Eur Urol , vol.1 , Issue.SUPPL. 1 , pp. 63
    • Gbekor, E.1    Bethell, S.2    Fawcett, L.3    Mount, N.4    Phillips, S.5
  • 20
    • 0035964782 scopus 로고    scopus 로고
    • Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor
    • 10.1016/S0024-3205(01)01308-X
    • Kim NN, Huang YH, Goldstein I, Bischoff E, Trais AM (2001) Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 69:2249-2256 10.1016/S0024-3205(01)01308-X
    • (2001) Life Sci , vol.69 , pp. 2249-2256
    • Kim, N.N.1    Huang, Y.H.2    Goldstein, I.3    Bischoff, E.4    Trais, A.M.5
  • 21
    • 17944364288 scopus 로고    scopus 로고
    • Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose
    • 10.1159/000049770
    • Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM (2001) Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 40:181-188 10.1159/000049770
    • (2001) Eur Urol , vol.40 , pp. 181-188
    • Stark, S.1    Sachse, R.2    Liedl, T.3    Hensen, J.4    Rohde, G.5    Wensing, G.6    Horstmann, R.7    Schrott, K.M.8
  • 22
    • 0037370684 scopus 로고    scopus 로고
    • Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction
    • 10.1177/0091270003043007003
    • Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P (2003) Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 43:260-267 10.1177/ 0091270003043007003
    • (2003) J Clin Pharmacol , vol.43 , pp. 260-267
    • Rajagopalan, P.1    Mazzu, A.2    Xia, C.3    Dawkins, R.4    Sundaresan, P.5
  • 23
    • 0000674216 scopus 로고    scopus 로고
    • Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor for the treatment of erectile dysfunction
    • Klotz T, Bauer RJ, Rohde G (2002) Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor for the treatment of erectile dysfunction. Pharmacotherapy 22:418
    • (2002) Pharmacotherapy , vol.22 , pp. 418
    • Klotz, T.1    Bauer, R.J.2    Rohde, G.3
  • 24
    • 0002752368 scopus 로고    scopus 로고
    • Dose normalized pharmacokinetics of tadalafil (IC351) in healthy volunteers
    • Patterson B, Bedding A, Jewell H, Payne C, Mitchell M (2001) Dose normalized pharmacokinetics of tadalafil (IC351) in healthy volunteers. Int J Impot Res 13(Suppl. 5):S62-A14
    • (2001) Int J Impot Res , vol.13 , Issue.SUPPL. 5
    • Patterson, B.1    Bedding, A.2    Jewell, H.3    Payne, C.4    Mitchell, M.5
  • 25
    • 31144450683 scopus 로고    scopus 로고
    • Cialis summary of product characteristics, EMEA Lilly ICOS Limited, November
    • Cialis summary of product characteristics, EMEA (2003), Lilly ICOS Limited, November
    • (2003)
  • 26
    • 0034724177 scopus 로고    scopus 로고
    • Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
    • 10.1073/pnas.050585197
    • Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, et al (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702 10.1073/pnas.050585197
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 3702
    • Fawcett, L.1    Baxendale, R.2    Stacey, P.3    McGrouther, C.4    Harrow, I.5    Soderling, S.6
  • 27
    • 0001860823 scopus 로고    scopus 로고
    • The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351)
    • Patterson B, Bedding A, Jewell H, Mitchell M (2001) The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 13(Suppl. 5):S43
    • (2001) Int J Impot Res , vol.13 , Issue.SUPPL. 5
    • Patterson, B.1    Bedding, A.2    Jewell, H.3    Mitchell, M.4
  • 28
    • 0038353576 scopus 로고    scopus 로고
    • Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial
    • 10.1016/S0090-4295(03)00359-5
    • Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R (2003) Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology 62:121-125 10.1016/S0090-4295(03)00359-5
    • (2003) Urology , vol.62 , pp. 121-125
    • Porst, H.1    Padma-Nathan, H.2    Giuliano, F.3    Anglin, G.4    Varanese, L.5    Rosen, R.6
  • 29
    • 31144448047 scopus 로고    scopus 로고
    • Cialis® (tadalafil) package insert, Food and Drug Administration Lilly ICOS LLC
    • Cialis® (tadalafil) package insert, Food and Drug Administration (2003), Lilly ICOS LLC
    • (2003)
  • 30
    • 0032898904 scopus 로고
    • Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction
    • Ashton AK, Bennett RG (1991) Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 60:194-195
    • (1991) J Clin Psychiatry , vol.60 , pp. 194-195
    • Ashton, A.K.1    Bennett, R.G.2
  • 31
    • 0032962101 scopus 로고    scopus 로고
    • Sildenafil for iatrogenic serotoninergic antidepressant medication-induced sexual dysfunction in 4 patients
    • Nurnberg HG, Lauriello J, Hensley PL, Parker LM, Keith SJ (1999) Sildenafil for iatrogenic serotoninergic antidepressant medication-induced sexual dysfunction in 4 patients. J Clin Psychiatry 60:33-35
    • (1999) J Clin Psychiatry , vol.60 , pp. 33-35
    • Nurnberg, H.G.1    Lauriello, J.2    Hensley, P.L.3    Parker, L.M.4    Keith, S.J.5
  • 32
    • 0032622397 scopus 로고    scopus 로고
    • Sildenafil citrate for SSRI-induced sexual side effects
    • Rosenberg KP (1999) Sildenafil citrate for SSRI-induced sexual side effects. Am J Psychiatry 156:157
    • (1999) Am J Psychiatry , vol.156 , pp. 157
    • Rosenberg, K.P.1
  • 33
    • 0035156333 scopus 로고    scopus 로고
    • A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction
    • 10.1046/j.1464-410x.2001.00998.x
    • Meuleman E, Cuzin B, Opsomer RJ, Hartmann U, Bailey MJ, Maytom MC, Smith MD, Osterloh IH (2001) A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 87:75-81 10.1046/j.1464-410x.2001.00998.x
    • (2001) BJU Int , vol.87 , pp. 75-81
    • Meuleman, E.1    Cuzin, B.2    Opsomer, R.J.3    Hartmann, U.4    Bailey, M.J.5    Maytom, M.C.6    Smith, M.D.7    Osterloh, I.H.8
  • 34
    • 0034780576 scopus 로고    scopus 로고
    • Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus
    • 10.1007/s001250100656
    • Boulton AJM, Selam JL, Sweeney M, Ziegler D (2001) Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 44:1296-1301 10.1007/s001250100656
    • (2001) Diabetologia , vol.44 , pp. 1296-1301
    • Boulton, A.J.M.1    Selam, J.L.2    Sweeney, M.3    Ziegler, D.4
  • 35
    • 0036755020 scopus 로고    scopus 로고
    • The efficacy of sildenafil citrate (Viagra) in clinical populations: An update
    • 10.1016/S0090-4295(02)01687-4
    • Carson CC, Burnett AL, Levine LA, Nehra A (2002) The efficacy of sildenafil citrate (Viagra) in clinical populations: An update. Urology 60(Suppl. 2):12-27 10.1016/S0090-4295(02)01687-4
    • (2002) Urology , vol.60 , Issue.SUPPL. 2 , pp. 12-27
    • Carson, C.C.1    Burnett, A.L.2    Levine, L.A.3    Nehra, A.4
  • 36
    • 0012624097 scopus 로고    scopus 로고
    • Sildenafil (Viagra™) for male erectile dysfunction: A meta-analysis of clinical trial reports
    • 10.1186/1471-2490-2-6
    • Moore RA, Edwards JE, McQuay HJ (2002) Sildenafil (Viagra™) for male erectile dysfunction: A meta-analysis of clinical trial reports. BMC Urol 2:6 10.1186/1471-2490-2-6
    • (2002) BMC Urol , vol.2 , pp. 6
    • Moore, R.A.1    Edwards, J.E.2    McQuay, H.J.3
  • 37
    • 0037166642 scopus 로고    scopus 로고
    • Sildenafil for male erectile dysfunction: A systematic review and meta-analysis
    • 10.1001/archinte.162.12.1349
    • Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile dysfunction: A systematic review and meta-analysis. Arch Intern Med 162:1349-1360 10.1001/archinte.162.12.1349
    • (2002) Arch Intern Med , vol.162 , pp. 1349-1360
    • Fink, H.A.1    MacDonald, R.2    Rutks, I.R.3    Nelson, D.B.4    Wilt, T.J.5
  • 38
    • 0035035922 scopus 로고    scopus 로고
    • Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire
    • 10.1016/S0090-4295(01)00945-1
    • Lewis R, Bennet CJ, Borkon WD, Boykin WH, Althoff SE, Stecher VJ, Siegel RL (2001) Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 57:960-965 10.1016/ S0090-4295(01)00945-1
    • (2001) Urology , vol.57 , pp. 960-965
    • Lewis, R.1    Bennet, C.J.2    Borkon, W.D.3    Boykin, W.H.4    Althoff, S.E.5    Stecher, V.J.6    Siegel, R.L.7
  • 39
    • 0033119838 scopus 로고    scopus 로고
    • EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction
    • 10.1016/S0090-4295(98)00582-2
    • Althof SE, Corty EW, Levine SB (1999) EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 53:793-799 10.1016/S0090-4295(98)00582-2
    • (1999) Urology , vol.53 , pp. 793-799
    • Althof, S.E.1    Corty, E.W.2    Levine, S.B.3
  • 40
    • 0036755170 scopus 로고    scopus 로고
    • A 4-year update on the safety of sildenafil citrate (Viagra)
    • 10.1016/S0090-4295(02)01752-1
    • Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F (2002) A 4-year update on the safety of sildenafil citrate (Viagra). Urology 60(2 Suppl 2):67-90 10.1016/S0090-4295(02)01752-1
    • (2002) Urology , vol.60 , Issue.2 SUPPL. 2 , pp. 67-90
    • Padma-Nathan, H.1    Eardley, I.2    Kloner, R.A.3    Laties, A.M.4    Montorsi, F.5
  • 41
    • 0242484067 scopus 로고    scopus 로고
    • Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy
    • Padma-Nathan E, McCullough AR, Giuliano F, Toler SM,Wohlhuter C, Shpilsky AB (2003) Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. J Urol 4(Suppl):375
    • (2003) J Urol , vol.4 , Issue.SUPPL. , pp. 375
    • Padma-Nathan, E.1    McCullough, A.R.2    Giuliano, F.3    Toler, S.M.4    Wohlhuter, C.5    Shpilsky, A.B.6
  • 42
    • 9644283025 scopus 로고    scopus 로고
    • Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis
    • 10.1016/j.eururo.2004.09.005
    • Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabè J, Burgess G, Wayman C, Alexandre L, Giuliano F (2005) Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis. Eur Urol 47:87-91 10.1016/ j.eururo.2004.09.005
    • (2005) Eur Urol , vol.47 , pp. 87-91
    • Behr-Roussel, D.1    Gorny, D.2    Mevel, K.3    Caisey, S.4    Bernabè, J.5    Burgess, G.6    Wayman, C.7    Alexandre, L.8    Giuliano, F.9
  • 43
    • 0033518552 scopus 로고    scopus 로고
    • Sildenafil for the treatment of erectile dysfunction in men with diabetes
    • 10.1001/jama.281.5.421
    • Rendell MS, Rajfer J, Wicker PA, Smith MD (1999) Sildenafil for the treatment of erectile dysfunction in men with diabetes. JAMA 281:421-426 10.1001/jama.281.5.421
    • (1999) JAMA , vol.281 , pp. 421-426
    • Rendell, M.S.1    Rajfer, J.2    Wicker, P.A.3    Smith, M.D.4
  • 44
    • 20444500162 scopus 로고    scopus 로고
    • Viagra® (sildenafil citrate): Efficacy and safety in the treatment of erectile dysfunction (ED) in men with diabetes
    • American Diabetes Association Meeting, 19-22 June, San Diego
    • Hirsch IB, Korenman SG, Stecher V, Diuguid C (1999) Viagra® (sildenafil citrate): Efficacy and safety in the treatment of erectile dysfunction (ED) in men with diabetes. In: American Diabetes Association Meeting, 19-22 June, San Diego
    • (1999)
    • Hirsch, I.B.1    Korenman, S.G.2    Stecher, V.3    Diuguid, C.4
  • 45
    • 0041364523 scopus 로고    scopus 로고
    • Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes mellitus. Results of a randomised controlled trial
    • 12547849
    • Stuckey B, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, Manzano P, Deerochanawong C (2003) Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes mellitus. Results of a randomised controlled trial. Diabetes Care 26:279-284 12547849
    • (2003) Diabetes Care , vol.26 , pp. 279-284
    • Stuckey, B.1    Jadzinsky, M.N.2    Murphy, L.J.3    Montorsi, F.4    Kadioglu, A.5    Fraige, F.6    Manzano, P.7    Deerochanawong, C.8
  • 46
    • 0034780576 scopus 로고    scopus 로고
    • Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus
    • 10.1007/s001250100656
    • Boulton AJM, Selam JL, Sweeney M, Ziegler D (2001) Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 44:1296-1301 10.1007/s001250100656
    • (2001) Diabetologia , vol.44 , pp. 1296-1301
    • Boulton, A.J.M.1    Selam, J.L.2    Sweeney, M.3    Ziegler, D.4
  • 48
    • 0037070232 scopus 로고    scopus 로고
    • Cardiovascular effects of sildenafil during exercise in men with known or probable CAD
    • 10.1001/jama.287.6.719
    • Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA (2002) Cardiovascular effects of sildenafil during exercise in men with known or probable CAD. JAMA 287:719-725 10.1001/jama.287.6.719
    • (2002) JAMA , vol.287 , pp. 719-725
    • Arruda-Olson, A.M.1    Mahoney, D.W.2    Nehra, A.3    Leckel, M.4    Pellikka, P.A.5
  • 49
    • 0033858827 scopus 로고    scopus 로고
    • Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure
    • 10.1016/S0735-1097(00)00790-7
    • Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36:845-851 10.1016/S0735-1097(00)00790-7
    • (2000) J Am Coll Cardiol , vol.36 , pp. 845-851
    • Katz, S.D.1    Balidemaj, K.2    Homma, S.3    Wu, H.4    Wang, J.5    Maybaum, S.6
  • 50
    • 0036868441 scopus 로고    scopus 로고
    • Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial
    • on behalf of the Vardenafil Study Group
    • Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H, on behalf of the Vardenafil Study Group (2002) Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 23:763-771
    • (2002) J Androl , vol.23 , pp. 763-771
    • Hellstrom, W.J.G.1    Gittelman, M.2    Karlin, G.3    Segerson, T.4    Thibonnier, M.5    Taylor, T.6    Padma-Nathan, H.7
  • 51
    • 0042405173 scopus 로고    scopus 로고
    • Vardenafil, a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study
    • 12610037
    • Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T (2003) Vardenafil, a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 26:777-783 12610037
    • (2003) Diabetes Care , vol.26 , pp. 777-783
    • Goldstein, I.1    Young, J.M.2    Fischer, J.3    Bangerter, K.4    Segerson, T.5    Taylor, T.6
  • 52
    • 0034868820 scopus 로고    scopus 로고
    • The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial
    • 10.1038/sj.ijir.3900713
    • Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T (2001) The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 13:192-199 10.1038/sj.ijir.3900713
    • (2001) Int J Impot Res , vol.13 , pp. 192-199
    • Porst, H.1    Rosen, R.2    Padma-Nathan, H.3    Goldstein, I.4    Giuliano, F.5    Ulbrich, E.6    Bandel, T.7
  • 53
    • 84995315685 scopus 로고    scopus 로고
    • Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction
    • 10.1111/j.1368-5031.2004.00128.x
    • Stief C, Porst H, de Tejada S, Ulbrich E, Beneke M (2004) Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 58:230-239 10.1111/ j.1368-5031.2004.00128.x
    • (2004) Int J Clin Pract , vol.58 , pp. 230-239
    • Stief, C.1    Porst, H.2    de Tejada, S.3    Ulbrich, E.4    Beneke, M.5
  • 54
    • 0043194001 scopus 로고    scopus 로고
    • Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy
    • 10.1097/01.ju.0000086947.00547.49
    • Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H (2003) Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 170:1278-1283 10.1097/01.ju.0000086947.00547.49
    • (2003) J Urol , vol.170 , pp. 1278-1283
    • Brock, G.1    Nehra, A.2    Lipshultz, L.I.3    Karlin, G.S.4    Gleave, M.5    Seger, M.6    Padma-Nathan, H.7
  • 55
    • 2942585404 scopus 로고    scopus 로고
    • Efficacy of vardenafil in men with erectile dysfunction: A flexible dose community practice study
    • on behalf of the Vardenafil Study Group
    • Potempa A-J, Ulbrich E, Bernard I, Beneke M, on behalf of the Vardenafil Study Group (2004) Efficacy of vardenafil in men with erectile dysfunction: A flexible dose community practice study. Eur Urol 46:73-79
    • (2004) Eur Urol , vol.46 , pp. 73-79
    • Potempa, A.-J.1    Ulbrich, E.2    Bernard, I.3    Beneke, M.4
  • 56
    • 1842687262 scopus 로고    scopus 로고
    • The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men
    • 10.1016/j.eururo.2004.01.014
    • Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel T, Porst H (2004) The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 45:634-641 10.1016/ j.eururo.2004.01.014
    • (2004) Eur Urol , vol.45 , pp. 634-641
    • Hatzichristou, D.1    Montorsi, F.2    Buvat, J.3    Laferriere, N.4    Bandel, T.5    Porst, H.6
  • 57
    • 12544256530 scopus 로고    scopus 로고
    • Vardenafil is effective and well tolerated for treating erectile dysfunction in a broad population of men, irrespective of age
    • Vardenafil Study Group
    • Giuliano F, Donatucci C, Montorsi F, Auerbach S, Karlin G, Norenberg C, Homering M, Segerson T, Eardley I, Vardenafil Study Group (2005) Vardenafil is effective and well tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int 95:110-116
    • (2005) BJU Int , vol.95 , pp. 110-116
    • Giuliano, F.1    Donatucci, C.2    Montorsi, F.3    Auerbach, S.4    Karlin, G.5    Norenberg, C.6    Homering, M.7    Segerson, T.8    Eardley, I.9
  • 58
    • 23944452949 scopus 로고    scopus 로고
    • Penetration and maintainence of erection with vardenafil: A time-from-dosing analysis
    • Vardenafil Study Group
    • Valiquette L, Montorsi F, Hellstrom WJ, Giuliano F, Homering M, Taylor T, Eardley I, Vardenafil Study Group (2005) Penetration and maintainence of erection with vardenafil: A time-from-dosing analysis. Can J Urol 12:2687-2698
    • (2005) Can J Urol , vol.12 , pp. 2687-2698
    • Valiquette, L.1    Montorsi, F.2    Hellstrom, W.J.3    Giuliano, F.4    Homering, M.5    Taylor, T.6    Eardley, I.7
  • 59
    • 23844458869 scopus 로고    scopus 로고
    • Vardenafil in patients with erectile dysfunction: Achieving treatment optimization
    • (200)
    • Hellstrom WJ, Elhilali M, Homering M, Taylor T, Gittleman M (200) Vardenafil in patients with erectile dysfunction: Achieving treatment optimization. J Androl 26:604-609
    • J Androl , vol.26 , pp. 604-609
    • Hellstrom, W.J.1    Elhilali, M.2    Homering, M.3    Taylor, T.4    Gittleman, M.5
  • 60
    • 10644262090 scopus 로고    scopus 로고
    • Vardenafil provides reliable efficacy over time in men with erectile dysfunction
    • North American and European Vardenafil Groups. 10.1016/ j.urology.2004.07.032
    • Montorsi F, Hellstrom WJ, Valiquette L, Bastuba M, Collins O, Taylor T, Thibonnier, Homering M, Eardley I (2004) North American and European Vardenafil Groups. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 64:1187-1195 10.1016/ j.urology.2004.07.032
    • (2004) Urology , vol.64 , pp. 1187-1195
    • Montorsi, F.1    Hellstrom, W.J.2    Valiquette, L.3    Bastuba, M.4    Collins, O.5    Taylor, T.6    Thibonnier7    Homering, M.8    Eardley, I.9
  • 61
    • 0037378435 scopus 로고    scopus 로고
    • Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial
    • on behalf of Vardenafil Study Group
    • Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H on behalf of Vardenafil Study Group (2003) Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61(4 Suppl. 1):8-14
    • (2003) Urology , vol.61 , Issue.4 SUPPL. 1 , pp. 8-14
    • Hellstrom, W.J.1    Gittelman, M.2    Karlin, G.3    Segerson, T.4    Thibonnier, M.5    Taylor, T.6    Padma-Nathan, H.7
  • 62
    • 18744376052 scopus 로고    scopus 로고
    • Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy
    • 10.1097/01.ju.0000158456.41788.93
    • Nehera A, Grantmyre J, Nadel A, Thibonnier M, Brock G (2005) Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 173:2067-2071 10.1097/ 01.ju.0000158456.41788.93
    • (2005) J Urol , vol.173 , pp. 2067-2071
    • Nehera, A.1    Grantmyre, J.2    Nadel, A.3    Thibonnier, M.4    Brock, G.5
  • 63
    • 0037021566 scopus 로고    scopus 로고
    • The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease
    • 10.1016/S0735-1097(02)02563-9
    • Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P (2002) The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 40:2006-2012 10.1016/S0735-1097(02)02563-9
    • (2002) J Am Coll Cardiol , vol.40 , pp. 2006-2012
    • Thadani, U.1    Smith, W.2    Nash, S.3    Bittar, N.4    Glasser, S.5    Narayan, P.6    Stein, R.A.7    Larkin, S.8    Mazzu, A.9    Tota, R.10    Pomerantz, K.11    Sundaresan, P.12
  • 64
    • 0001064956 scopus 로고    scopus 로고
    • Cialis (IC351) provides prompt response and extended period of responsiveness in the treatment of men with erectile dysfunction (ED)
    • Padma-Nathan H, Rosen RC, Shabsigh R et al (2001) Cialis (IC351) provides prompt response and extended period of responsiveness in the treatment of men with erectile dysfunction (ED). J Urol 165(Suppl):A923
    • (2001) J Urol , vol.165 , Issue.SUPPL.
    • Padma-Nathan, H.1    Rosen, R.C.2    Shabsigh, R.3
  • 65
    • 0035070379 scopus 로고    scopus 로고
    • On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction
    • 10.1038/sj.ijir.3900631
    • Padma-Nathan H, McMurray JG, Pullman WE et al (2001) On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13:2-9 10.1038/sj.ijir.3900631
    • (2001) Int J Impot Res , vol.13 , pp. 2-9
    • Padma-Nathan, H.1    McMurray, J.G.2    Pullman, W.E.3
  • 66
    • 0036783940 scopus 로고    scopus 로고
    • Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses
    • 10.1097/00005392-200210010-00006
    • Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 168:1332 10.1097/ 00005392-200210010-00006
    • (2002) J Urol , vol.168 , pp. 1332
    • Brock, G.B.1    McMahon, C.G.2    Chen, K.K.3    Costigan, T.4    Shen, W.5    Watkins, V.6
  • 67
    • 21144476846 scopus 로고    scopus 로고
    • Efficacy and safety of tadalafil scheduled vs. on demand in men with erectile dysfunction: The SURE Study
    • for the SURE Study Investigators
    • Mirone V, van Ahlen H. for the SURE Study Investigators (2005) Efficacy and safety of tadalafil scheduled vs. on demand in men with erectile dysfunction: The SURE Study. Eur Urol 47:846-854
    • (2005) Eur Urol , vol.47 , pp. 846-854
    • Mirone, V.1    van Ahlen, H.2
  • 68
    • 12344288164 scopus 로고    scopus 로고
    • Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk
    • 10.1016/j.eururo.2004.10.002
    • Rosano G, Aversa A, Vitale C, Fabbri A, Fini M, Spera G (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47:214-222 10.1016/ j.eururo.2004.10.002
    • (2005) Eur Urol , vol.47 , pp. 214-222
    • Rosano, G.1    Aversa, A.2    Vitale, C.3    Fabbri, A.4    Fini, M.5    Spera, G.6
  • 70
    • 1842852557 scopus 로고    scopus 로고
    • Effets of tadalafil on erectile dysfunction in men with dibetes
    • 12453954
    • Sáenz de Tejada I, Anglin G, Knight JR, Emmick J (2002) Effets of tadalafil on erectile dysfunction in men with dibetes. Diabetes Care 25:2159-2164 12453954
    • (2002) Diabetes Care , vol.25 , pp. 2159-2164
    • Sáenz de Tejada, I.1    Anglin, G.2    Knight, J.R.3    Emmick, J.4
  • 71
    • 31144438801 scopus 로고    scopus 로고
    • Tadalafil improves erectile function in men with erectile dysfunction and diabetes mellitus
    • 10.1038/sj.ijir.3900943
    • Strojek K, Price D, Fonseca V, Fredlund P (2003) Tadalafil improves erectile function in men with erectile dysfunction and diabetes mellitus. Int J Impot Res 15(Suppl 6):S26 10.1038/sj.ijir.3900943
    • (2003) Int J Impot Res , vol.15 , Issue.SUPPL. 6
    • Strojek, K.1    Price, D.2    Fonseca, V.3    Fredlund, P.4
  • 72
    • 2642539623 scopus 로고    scopus 로고
    • Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: A randomized, double-blind, placebo-controlled trial
    • 10.1097/01.ju.0000136448.71773.2b
    • Montorsi F, McCullough A, Brock GB et al (2004) Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: A randomized, double-blind, placebo-controlled trial. J Urol 172:1036-1041 10.1097/ 01.ju.0000136448.71773.2b
    • (2004) J Urol , vol.172 , pp. 1036-1041
    • Montorsi, F.1    McCullough, A.2    Brock, G.B.3
  • 73
    • 0242460582 scopus 로고    scopus 로고
    • Cardiovascular effects of tadalafil in patients on common antihypertensive therapy
    • 10.1016/S0002-9149(03)00075-4
    • Kloner RA, Mitchell M, Emmick JT (2003) Cardiovascular effects of tadalafil in patients on common antihypertensive therapy. Am J Cardiol 92(Suppl. 1):47-57 10.1016/S0002-9149(03)00075-4
    • (2003) Am J Cardiol , vol.92 , Issue.SUPPL. 1 , pp. 47-57
    • Kloner, R.A.1    Mitchell, M.2    Emmick, J.T.3
  • 74
    • 0242552045 scopus 로고    scopus 로고
    • Time course of the interaction between tadalafil and nitrates
    • Kloner RA, Hutter AM, Emmick JT, et al (2003) Time course of the interaction between tadalafil and nitrates. JACC 42:1885-1860
    • (2003) JACC , vol.42 , pp. 1860-1885
    • Kloner, R.A.1    Hutter, A.M.2    Emmick, J.T.3
  • 75
    • 0042236843 scopus 로고    scopus 로고
    • Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones
    • 10.1097/01.ju.0000081053.97792.da
    • Hellstrom WJG, Overstreet JW, Yu A et al (2003) Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 170:887-891 10.1097/01.ju.0000081053.97792.da
    • (2003) J Urol , vol.170 , pp. 887-891
    • Hellstrom, W.J.G.1    Overstreet, J.W.2    Yu, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.